Ba/F3 cells and their use in kinase drug discovery
The DOI matches its Crossref record; 60 of the 60 references it cites were found in a registry or an index.
Abstract
Purpose of review Due to their ability to function as dominant oncogenes, protein kinases have become favored targets in the quest for 'molecularly-targeted' cancer chemotherapeutics. The discovery of a large number of cancer-associated mutations in the kinome, and the progress in developing specific small-molecule kinase inhibitors has increased the need for accurate, reproducible, and efficient kinase activity-dependent cellular assay systems. Recent findings Ba/F3, a murine interleukin-3 dependent pro-B cell line is increasingly popular as a model system for assessing both the potency and downstream signaling of kinase oncogenes, and the ability of small-molecule kinase inhibitors to block kinase activity. Facilitated by their growth properties, Ba/F3 cells have recently been adapted to high-throughput assay formats for compound profiling. Further, several published approaches show promise in predicting resistance to small-molecule kinase inhibitors elicited by point mutations interfering with inhibitor binding. Summary Ba/F3 cells are an increasingly popular tool in kinase drug discovery. The ability to test the transforming capacity of newly identified kinase mutations, and to profile drug candidates and compound libraries in high-throughput fashion, combined with the use of Ba/F3 cells to predict clinical resistance will greatly facilitate developments in this field.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Citations
Cites
Lynch, T. J., Bell, D. W., Sordella, R., Gurubhagavatula, S., Okimoto, R. A., Brannigan, B. W., Harris, P. L., Haserlat, S. M., Supko, J. G., Haluska, F. G., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040938 · Cited by 11,486
EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy
Paez, J. G., Jänne, P. A., Lee, J. C., Tracy, S., Greulich, H., Gabriel, S., Herman, P., Kaye, F. J., Lindeman, N., Boggon, T. J., et al. (2004) · Science · doi:10.1126/science.1099314 · Cited by 9,368
EGFR Mutation and Resistance of Non–Small-Cell Lung Cancer to Gefitinib
Kobayashi, S., Boggon, T. J., Dayaram, T., Jänne, P. A., Kocher, O., Meyerson, M., Johnson, B. E., Eck, M. J., Tenen, D. G., & Halmos, B. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa044238 · Cited by 3,964
Blume-Jensen, P., & Hunter, T. (2001) · Nature · doi:10.1038/35077225 · Cited by 3,738
Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders
Baxter, E. J., Scott, L. M., Campbell, P. J., East, C., Fourouclas, N., Swanton, S., Vassiliou, G. S., Bench, A. J., Boyd, E. M., Curtin, N., et al. (2005) · The Lancet · doi:10.1016/s0140-6736(05)71142-9 · Cited by 3,548
A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera
James, C., Ugo, V., Le Couédic, J.-P., Staerk, J., Delhommeau, F., Lacout, C., Garçon, L., Raslova, H., Berger, R., Bennaceur-Griscelli, A., et al. (2005) · Nature · doi:10.1038/nature03546 · Cited by 3,544
A Gain-of-Function Mutation of JAK2 in Myeloproliferative Disorders
Kralovics, R., Passamonti, F., Buser, A. S., Teo, S.-S., Tiedt, R., Passweg, J. R., Tichelli, A., Cazzola, M., & Skoda, R. C. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa051113 · Cited by 3,470
Clinical Resistance to STI-571 Cancer Therapy Caused by BCR-ABL Gene Mutation or Amplification
Gorre, M. E., Mohammed, M., Ellwood, K., Hsu, N., Paquette, R., Rao, P. N., & Sawyers, C. L. (2001) · Science · doi:10.1126/science.1062538 · Cited by 3,104
Levine, R. L., Wadleigh, M., Cools, J., Ebert, B. L., Wernig, G., Huntly, B. J. P., Boggon, T. J., Wlodarska, I., Clark, J. J., Moore, S., et al. (2005) · Cancer Cell · doi:10.1016/j.ccr.2005.03.023 · Cited by 2,993
Hematologic and Cytogenetic Responses to Imatinib Mesylate in Chronic Myelogenous Leukemia
Kantarjian, H., Sawyers, C., Hochhaus, A., Guilhot, F., Schiffer, C., Gambacorti-Passerini, C., Niederwieser, D., Resta, D., Capdeville, R., Zoellner, U., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa011573 · Cited by 2,019
Cited by
Items 101–200 of 268
Manley, P. W., Caravatti, G., Furet, P., Roesel, J. L., Tran, P., Wagner, T., & Wartmann, M. (2018) · Biochemistry · doi:10.1021/acs.biochem.8b00727 · Cited by 27
Diculescu, V. C., & Enache, T. A. (2014) · Analytica Chimica Acta · doi:10.1016/j.aca.2014.06.025 · Cited by 26
Narayanan, R., Yepuru, M., Coss, C. C., Wu, Z., Bauler, M. N., Barrett, C. M., Mohler, M. L., Wang, Y., Kim, J., Snyder, L. M., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0083380 · Cited by 23
“Over-expression of proto-oncogenes facilitates the normally IL3-dependent Ba/F3 cells (murine B cells) to grow in the absence of IL-3 and hence this model was utilized to demonstrate the effects of GTx-186 [45].”
MethodPeipp, M., Schneider‐Merck, T., Dechant, M., Beyer, T. D., van Bueren, J. J. L., Bleeker, W. K., Parren, P. W. H. I., van de Winkel, J. G. J., & Valerius, T. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.180.6.4338 · Cited by 24
“Ba/F3 is an IL-3-dependent murine pro-B cell line, which has been used before to study signaling by growth factor receptors (34).”
BackgroundEstevam, G. O., Linossi, E. M., Macdonald, C. B., Espinoza, C. A., Michaud, J. M., Coyote-Maestas, W., Collisson, E. A., Jura, N., & Fraser, J. S. (2024) · eLife · doi:10.7554/elife.91619 · Cited by 22
“IL-3 IL-3 was added to wells at 0-10ng/ml (0, 0.078, 0.16, 0.31, 1.3, 2.5, 5, 10 ng/ml).”
InfluentialTropomyosin receptor kinase inhibitors: a patent update 2009 – 2013
McCarthy, C., & Walker, E. R. H. (2014) · Expert Opinion on Therapeutic Patents · doi:10.1517/13543776.2014.910195 · Cited by 24
“Extensive biological data are provided in Trk isoform-specific Tel-BAF3 proliferation assays together with the control parental BAF3 cell line [52].”
MethodAkt shows variable sensitivity to an Hsp90 inhibitor depending on cell context
Theodoraki, M. A., Kunjappu, M., Sternberg, D., & Caplan, A. J. (2007) · Experimental Cell Research · doi:10.1016/j.yexcr.2007.06.022 · Cited by 23
“Ba/F3 is a pro-B cell line that is immortal but depends on the cytokine IL-3 for growth [17, 18].”
BackgroundFluorescent Visualization of Src by Using Dasatinib‐BODIPY
Vetter, M. L., Zhang, Z., Liu, S., Wang, J., Cho, H., Zhang, J., Zhang, W., Gray, N. S., & Yang, P. L. (2014) · ChemBioChem · doi:10.1002/cbic.201402010 · Cited by 20
Discovery of Allosteric Bcr–Abl Inhibitors from Phenotypic Screen to Clinical Candidate
Gray, N. S., & Fabbro, D. (2014) · Methods in enzymology on CD-ROM/Methods in enzymology · doi:10.1016/b978-0-12-397918-6.00007-0 · Cited by 20
“Thus, 32D or Ba/F3 cells transformed with oncogenic TKs have become a powerful tool for the discovery and optimization of TK inhibitors because a simple proliferation assays in conjunction with the autophosphorylation status (by ELISA) of the oncogenic TK provides accurate structure–activity relationships that faithfu…”
MethodWu, M. H., Huang, J., Zhang, J., Benes, C. H., Jiao, B., & Ren, R. (2017) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-16-0419 · Cited by 21
“Ba/F3, a murine bone marrow–derived cell line depending on IL3 for viability and proliferation (26), has been successfully used in high-throughput assays for kinase drug discoveries (27).”
MethodGui, F., Jiang, J., He, Z., Li, L., Li, Y., Deng, Z., Lu, Y., Wu, X., Chen, G., Su, J., et al. (2019) · British Journal of Pharmacology · doi:10.1111/bph.14809 · Cited by 21
Kong, K., Ng, P. K., & Scott, K. L. (2017) · Oncotarget · doi:10.18632/oncotarget.17828 · Cited by 19
Choi, J., Shin, J. H., Kim, T. K., Kim, K., Kim, J.-Y., Jeon, E., Park, J., Han, Y. D., Kim, K., Sim, T., et al. (2024) · Cancer Letters · doi:10.1016/j.canlet.2024.216904 · Cited by 21
A noncanonical FLT3 gatekeeper mutation disrupts gilteritinib binding and confers resistance
Joshi, S. K., Sharzehi, S., Pittsenbarger, J., Bottomly, D., Tognon, C. E., McWeeney, S. K., Druker, B. J., & Traer, E. A. (2021) · American Journal of Hematology · doi:10.1002/ajh.26174 · Cited by 18
Microcup Arrays for the Efficient Isolation and Cloning of Cells
Xu, W., Sims, C. E., & Allbritton, N. L. (2010) · Analytical Chemistry · doi:10.1021/ac100434v · Cited by 23
Estevam, G. O., Linossi, E., Rao, J., Macdonald, C. B., Ravikumar, A., Chrispens, K. M., Capra, J. A., Coyote-Maestas, W., Pimentel, H., Collisson, E. A., et al. (2025) · eLife · doi:10.7554/elife.101882 · Cited by 17
Emergence of CTNNB1 mutation at acquired resistance to KIT inhibitor in metastatic melanoma
Cho, J., Kim, S. Y., Kim, Y. J., Sim, M.-S., Kim, S. T., Kim, N. K. D., Kım, K., Park, W., Kim, J. H., Jang, K., et al. (2017) · Clinical & Translational Oncology · doi:10.1007/s12094-017-1662-x · Cited by 17
“Ba/F3, a murine interleukin 3 (IL3)-dependent pro-B cell line, is increasingly popular as a model system for assessing the ability of small molecule kinase inhibitors to block kinase activity and for predicting resistance to small molecule kinase inhibitors elicited by point mutations [17].”
BackgroundSelf-citationYu, S., Zhang, Y., Pan, Y., Cheng, C., Sun, Y., & Chen, H. (2017) · OncoTargets and Therapy · doi:10.2147/ott.s131999 · Cited by 20
Jang, J., To, C., Clercq, D. J. H. D., Park, E., Ponthier, C. M., Shin, B. H., Mushajiang, M., Nowak, R. P., Fischer, E. S., Eck, M. J., et al. (2020) · Angewandte Chemie · doi:10.1002/ange.202003500 · Cited by 18
Zhang, Y., Chan, S., He, R., Liu, Y., Song, X., Tu, Z., Ren, X., Zhou, Y., Zhang, Z., Wang, Z., et al. (2022) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2022.114862 · Cited by 18
Allosteric Regulation of Switch-II Domain Controls KRAS Oncogenicity
Yang, M. H., Tran, T. H., Hunt, B., Agnor, R., Johnson, C. W., Shui, B., Waybright, T. J., Nowak, J. A., Stephen, A. G., Simanshu, D. K., et al. (2023) · Cancer Research · doi:10.1158/0008-5472.can-22-3210 · Cited by 17
Xia, Z., Ji, Y., Sun, D., Xia, P., Gao, Y., Fang, Y., Zhao, X., Wang, W., Ding, J., Geng, M., et al. (2020) · Acta Pharmacologica Sinica · doi:10.1038/s41401-020-00513-3 · Cited by 16
“Furthermore, we generated a “ROS1-dependent” context by introducing a CD74–ROS1 fusion using a mouse pro-B BaF3 cell line that is recognized to be dependent on IL-3 for survival, and the introduction of oncogenic kinases allows cell growth to be independent of IL-3 [15, 16].”
Quantitative Phosphoproteomics Analysis of ERBB3/ERBB4 Signaling
Wandinger, S. K., Lahortiga, I., Jacobs, K., Klammer, M., Jordan, N., Elschenbroich, S., Paradé, M., Jacoby, E., Linders, J. T. M., Brehmer, D., et al. (2016) · PLoS ONE · doi:10.1371/journal.pone.0146100 · Cited by 17
“Ba/F3 is an interleukin-3 (IL3) dependent B-cell line that has been widely used to study oncogenic activities of kinases, and as a tool for screening and development of kinase inhibitors [37].”
MethodWatanabe‐Smith, K., Godil, J. A., Agarwal, A., Tognon, C. E., & Druker, B. J. (2017) · Oncotarget · doi:10.18632/oncotarget.15392 · Cited by 17
“com/oncotarget transformed Ba/F3 cells are frequently used for pathway analysis to characterize mechanisms of oncogenic signaling or to test the effects of selective targeted inhibitors on cell growth and survival [5].”
BackgroundPreclinical Evaluation of the FGFR-Family Inhibitor Futibatinib for Pediatric Rhabdomyosarcoma
Wu, J. T., Cheuk, A., Isanogle, K. A., Robinson, C. M., Zhang, X., Ceribelli, M., Beck, E., Shinn, P., Klumpp-Thomas, C. A., Wilson, K. M., et al. (2023) · Cancers · doi:10.3390/cancers15164034 · Cited by 15
“Ba/F3 is a murine, interleukin (IL)-3 dependent cell line that can be rendered IL-3 independent with the introduction of a constitutively active kinase [23,24].”
BackgroundTP63 fusions drive multicomplex enhancer rewiring, lymphomagenesis, and EZH2 dependence
Wu, G., Yoshida, N., Liu, J., Zhang, X., Xiong, Y., Heavican, T. B., Mandato, E., Liu, H., Nelson, G. M., Yang, L., et al. (2023) · Science Translational Medicine · doi:10.1126/scitranslmed.adi7244 · Cited by 16
“Expression of TBL1XR1::TP63 in pro-B Ba/F3 cells, which are rendered interleukin-3 (IL-3)–independently when transformed by a variety of oncogenes (15), conferred IL-3–independent growth (Fig.”
Trans-activating mutations of the pseudokinase ERBB3
Koivu, M. K. A., Chakroborty, D., Airenne, T. T., Johnson, M. S., Kurppa, K. J., & Elenius, K. (2024) · Oncogene · doi:10.1038/s41388-024-03070-9 · Cited by 15
“…in domain II of ERBB3 just after the dimerization arm, at the beginning of module 5, a module in direct contact with the dimerization arm of ERBB2, thereby potentially affecting dimer formation and stability; it is known that modules 2 – 7 of domain II are sensitive to alterations as demonstrated…”
BackgroundSPSB1 enhances ovarian cancer cell survival by destabilizing p21
Kim, H.-J., Kim, H. J., Kim, M., Bae, M. K., Sung, H. Y., Ahn, J., Kim, Y. H., Kim, S. C., & Ju, W. (2019) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2019.01.088 · Cited by 15
Self-citationFairhurst, R. A., Furet, P., Imbach, P. A., Stauffer, F., Rueeger, H., McCarthy, C., Ripoche, S., Oswald, S., Arnaud, B., Jary, A., et al. (2022) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.2c00267 · Cited by 16
Li, J., Tan, G., Cai, Y., Liu, R., Xiong, X., Gu, B., He, W., Liu, B., Ren, Q., Wu, J., et al. (2021) · Biochemical Pharmacology · doi:10.1016/j.bcp.2021.114620 · Cited by 15
Naturally occurring and synthetic constitutive-active cytokine receptors in disease and therapy
Floss, D. M., & Scheller, J. (2019) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2019.05.007 · Cited by 15
Liang, X., Wang, C., Wang, B., Liu, J., Qi, S., Wang, A., Liu, Q., Deng, M., Wang, L., Liu, J. L., et al. (2022) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2022.114782 · Cited by 15
Richards, C. E., Elamin, Y. Y., Carr, A., Gately, K. A., Rafee, S., Cremona, M., Hanrahan, E. O., Smyth, R., Ryan, D., Morgan, R. K., et al. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241310545 · Cited by 14
“Ba/F3 is a widely used pro-B cell line that is dependent on interleukin-3 (IL-3) for survival and proliferation but becomes IL-3 independent in the presence of an oncogene [26].”
RetractedAnti-cancer activity of 5-O-alkyl 1,4-imino-1,4-dideoxyribitols
Bello, C., Bello, G. D., Cea, M., Nahimana, A., Aubry, D., Garuti, A., Motta, G., Morán, E., Fruscione, F., Pronzato, P., et al. (2011) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2011.07.053 · Cited by 15
Liu, C., Jiao, B., Wang, P., Zhang, B., Gao, J., Li, D., Xie, X., Yao, Y., Yan, L., Qin, Z., et al. (2024) · Cell Communication and Signaling · doi:10.1186/s12964-024-01498-w · Cited by 13
A cell-based high-throughput screen for epidermal growth factor receptor pathway inhibitors
Lin, W., Song, J., Chang, T., Chang, C., Fu, Y.-N., Yeh, C.-L., Wu, S., Huang, Y.-W., Fang, M., Lien, T., et al. (2008) · Analytical Biochemistry · doi:10.1016/j.ab.2008.02.027 · Cited by 13
Byrgazov, K., Lucini, C. B., Berkowitsch, B., Koenig, M., Haas, O. A., Hoermann, G., Valent, P., & Lion, T. (2016) · Oncotarget · doi:10.18632/oncotarget.12943 · Cited by 13
“com/oncotarget discovery and characterization of other oncogenic tyrosine kinases [21].”
BackgroundConstruction and Deciphering of Human Phosphorylation-Mediated Signaling Transduction Networks
Zhang, M., Li, H., He, Y., Sun, H., Li, X., Wang, L., Sun, B., Ma, L., Zhang, G., Li, J., et al. (2015) · Journal of Proteome Research · doi:10.1021/acs.jproteome.5b00249 · Cited by 13
Mechanisms of targeted therapy resistance in a pediatric glioma driven by ETV6-NTRK3 fusion
Keddy, C., Neff, T. L., Huan, J., Nickerson, J. P., Beach, C. Z., Akkari, Y. M. N., Ji, J., Moore, S. R., Nazemi, K. J., Corless, C. L., et al. (2021) · Molecular Case Studies · doi:10.1101/mcs.a006109 · Cited by 15
“To further explore the TKI resistance profile of NTRK3 G623E mutation, we used the Ba/F3 heterologous model system (Warmuth et al. 2007; Davare et al. 2015; Drilon et al. 2016b; Somwar et al. 2020).”
Developing assays for kinase drug discovery – where have the advances come from?
Vogel, K. W., Zhong, Z., Bi, K., & Pollok, B. A. (2007) · Expert Opinion on Drug Discovery · doi:10.1517/17460441.3.1.115 · Cited by 11
“The use of Ba/F3 cells in these applications has been extensively reviewed [77] .”
BackgroundA RET::GRB2 fusion in pheochromocytoma defies the classic paradigm of RET oncogenic fusions
Estrada-Zuniga, C. M., Cheng, Z., Ethiraj, P., Guo, Q., Gonzalez‐Cantu, H., Adderley, E., Lopez, H., Landry, B. N., Zainal, A., Aronin, N., et al. (2022) · Cell Reports Medicine · doi:10.1016/j.xcrm.2022.100686 · Cited by 13
“4 Cell Reports Medicine 3, 100686, July 19, 2022 oncogenic transformation.(15,16) We generated Ba/F3 cells stably expressing the RET::GRB2 construct (Figure 3A) and a kinasedead (KD) version of this fusion, RET::GRB2 KD, carrying a K758 Mmutation known to render RET catalytically inactive.”
MethodSaifudeen, M., Zhu, S., Liang, S., Eason, M. M., Goupil, A., Mische, D., Loc’h, C., Ma, H., Chan, M., & Gujral, T. S. (2026) · Nature Biotechnology · doi:10.1038/s41587-026-03090-8 · Cited by 12
Ruzzi, F., Angelicola, S., Landuzzi, L., Nironi, E., Semprini, M. S., Scalambra, L., Altimari, A., Gruppioni, E., Fiorentino, M., Giunchi, F., et al. (2022) · Translational Lung Cancer Research · doi:10.21037/tlcr-22-163 · Cited by 10
“In the absence, several studies also used the transformed murine Ba/F3 interleukin-3 dependent pro-B cell line (34) expressing different ROS1 fusion genes to investigate TKI activity (3).”
Denitrogenative Alkylation of K-Ras(G12D) Inhibits Oncogenic Signaling in Cancer Cells
Zheng, Q., & Shokat, K. M. (2025) · Journal of the American Chemical Society · doi:10.1021/jacs.5c06745 · Cited by 9
Antitarget Selectivity and Tolerability of Novel Pyrrolo[2,3-d]pyrimidine RET Inhibitors
Mathison, C. J. N., Yang, Y., Nelson, J. T., Huang, Z., Jiang, J., CHIANELLI, D., Rucker, P. V., Roland, J. T., Xie, Y. F., Epple, R., et al. (2021) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.1c00450 · Cited by 9
Discovery of 3,5-diaryl-1H-pyrazol-based ureas as potent RET inhibitors
Wu, K., He, R., Li, Z., Qiu, K., Xiao, G., Peng, L., Meng, X., Zheng, C., Zhang, Z., & Cai, Q. (2023) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2023.115237 · Cited by 9
Subtel’na, I., Kryshchyshyn‐Dylevych, A., Jia, R., Lelyukh, M. I., Ringler, A., Kubicek, S., Zagrijtschuk, O., Královics, R., & Lesyk, R. (2020) · Archiv der Pharmazie · doi:10.1002/ardp.202000342 · Cited by 9
Fortschegger, K., Husa, A.-M., Schinnerl, D., Nebral, K., & Strehl, S. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22147576 · Cited by 10
“To prove activation of this pathway, generally, murine lymphoid Ba/F3 cells are used, which upon kinase activation acquire cytokineindependent growth and display enhanced phosphorylation of STAT1, STAT3, and STAT5 (pSTAT1/3/5) [9,35,36].”
BackgroundMa, H., Cui, J., Liu, Z., Fang, W., Lu, S., Cao, S., Zhang, Y., Chen, J., Lu, L., Xie, Q., et al. (2023) · Oncogene · doi:10.1038/s41388-023-02848-7 · Cited by 8
An intracellular conformational sensor assay for Abl T315I
Zhou, V. W., Gao, X., Han, S., Brinker, A., Caldwell, J. S., & Gu, X.-J. (2008) · Analytical Biochemistry · doi:10.1016/j.ab.2008.11.015 · Cited by 8
“Due to the short treatment times, typical artifacts originating from nonspecifically cytotoxic compounds could be avoided [26,27].”
BackgroundSelf-citationGoetz, E. M., & Garraway, L. A. (2012) · American Society of Clinical Oncology Educational Book · doi:10.14694/edbook_am.2012.32.189 · Cited by 8
Strategies for the treatment of acute myeloid leukemia with FLT3 mutations: a patent review
Górecki, L., Řezníčková, E., Kryštof, V., Řezáčová, M., Čečková, M., & Korábečný, J. (2024) · Expert Opinion on Therapeutic Patents · doi:10.1080/13543776.2024.2446224 · Cited by 7
“…is a murine interleukin-3 (IL-3) dependent pro-B cell line; it has become an extensively pursued tool in kinase drug development, because it can be easily modified and some kinases (including FLT3) render the cells independent of IL-3, while corresponding inhibitors can counteract this effect [57].”
Identification of novel FLT3 kinase inhibitors
Pauwels, D., Klaassen, H., Lahortiga, I., Kilonda, A., Jacobs, K., Sweron, B., Corbau, R., Chaltin, P., Marchand, A., & Cools, J. (2013) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2013.03.024 · Cited by 8
Shahar, O., Pereman, I., Khamisie, H., Ezov, N., Danay, O., Khattib, A., Schweitzer, R., Khatib, S., & Mahajna, J. A. (2023) · Heliyon · doi:10.1016/j.heliyon.2023.e13756 · Cited by 7
“This system has been used to assay anti-kinase activity in substances of interest [22,23] and also by our group to identify mushroom-derived substances that inhibit kinase activity of native and mutated BCR/ABL [15].”
MethodInfluentialZhao, Y., He, C., Zhang, D., Guo, Y., Peng, Z., Yu, L., Li, N., Chen, C., Zhao, Z. J., & Chen, Y. (2023) · Experimental Hematology and Oncology · doi:10.1186/s40164-023-00379-1 · Cited by 7
“The IL-3-dependent pro-B-cell line Ba/F3 is the most popular system to generate models with oncogene dependency and vulnerability to targeted drugs [6].”
BackgroundKurup, S., Gesinski, D., Assaad, K., & Reynolds, A. J. (2024) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2024.129612 · Cited by 8
Wang, F., Chen, Y., Yang, J., & Akutsu, T. (2022) · Scientific Reports · doi:10.1038/s41598-021-04230-7 · Cited by 8
Modeling pediatric AML FLT3 mutations using CRISPR/Cas12a- mediated gene editing
Rivera-Torres, N., Banas, K. H., & Kmiec, E. B. (2020) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2020.1805740 · Cited by 7
“The murine pro-B cell Ba/F3 cell line is dependent on IL-3 for growth and in the absence of IL-3 the cells undergo cell cycle arrest and apoptosis (33).”
BackgroundMiyanaga, A., Matsumoto, M., Beck, J. A., Horikawa, I., Oike, T., Okayama, H., Tanaka, H., Burkett, S. S., Robles, A. I., Ma, K., et al. (2021) · BMC Cancer · doi:10.1186/s12885-021-07905-6 · Cited by 7
Reversible control of kinase signaling through chemical-induced dephosphorylation
Sun, Y., Zhou, R., Hu, J., Feng, S., & Hu, Q. (2024) · Communications Biology · doi:10.1038/s42003-024-06771-9 · Cited by 6
“Ba/F3 cells are a murine pro-B cell line frequently used in the study of oncogenic kinases due to their dependenceoninterleukin-3(IL-3)forsurvival,whichcanbeoverriddenby oncogenicmutationsinthekinases 22 .”
BackgroundKarvonen, H., Raivola, J., & Ungureanu, D. (2022) · Methods in enzymology on CD-ROM/Methods in enzymology · doi:10.1016/bs.mie.2022.03.038 · Cited by 6
Estevam, G. O., Linossi, E., Rao, J., Macdonald, C. B., Ravikumar, A., Chrispens, K. M., Capra, J. A., Coyote-Maestas, W., Pimentel, H., Collisson, E. A., et al. (2025) · eLife · doi:10.7554/elife.101882.3 · Cited by 6
Development of a siRNA and shRNA screening system based on a kinase fusion protein
Pieraets, S., Cox, L., Gielen, O., & Cools, J. (2012) · RNA · doi:10.1261/rna.030015.111 · Cited by 6
“For our system, we used a truncated form of PDGFRa (named ‘‘tPDGFRa’’), known to be constitutively activated and to stimulate the proliferation and survival of Ba/F3 cells in the absence of IL-3 (Cools et al. 2003a,b; Stover et al. 2006; Warmuth et al. 2007).”
BackgroundMethodReport on the use of non‐clinical studies in the regulatory evaluation of oncology drugs
Hayakawa, Y., Kawada, M., Nishikawa, H., Ochiya, T., Saya, H., Seimiya, H., Yao, R., Hayashi, M., Kai, C., Matsuda, A., et al. (2016) · Cancer Science · doi:10.1111/cas.12857 · Cited by 7
An Unbiased Functional Genetics Screen Identifies Rare Activating ERBB4 Mutations
Chakroborty, D., Ojala, V. K., Knittle, A. M., Drexler, J., Tamirat, M. Z., Ruzicka, R., Bosch, K., Woertl, J., Schmittner, S., Elo, L. L., et al. (2022) · Cancer Research Communications · doi:10.1158/2767-9764.crc-21-0021 · Cited by 7
“While optimal for screening kinase-dependent growth (55), it is important to keep in mind that the Ba/F3 cells used here as the cellular background for the screen are murine hematopoietic cells (54), and thus considered ontologically distant from lineages that form solid tumors.”
BackgroundKiss, R., Bajusz, D., Baskin, R., Tóth, K., Monostory, K., Sayeski, P. P., & Keserű, G. M. (2016) · Archiv der Pharmazie · doi:10.1002/ardp.201600246 · Cited by 6
Novel insight into mechanisms of ROS1 catalytic activation via loss of the extracellular domain
Jones, K. L., Keddy, C., Jenkins, C., Nicholson, K. S., Shinde, U. P., & Davare, M. A. (2024) · Scientific Reports · doi:10.1038/s41598-024-71687-7 · Cited by 5
“The murine interleukin-3 (IL-3) dependent Ba/F3 cells undergo reproducible apoptotic cell death in the absence of the requisite IL-3, however exogenous expression of oncogenic protein variants, particularly kinases, confers continuous IL-3 independent cell growth 44,45 .”
BackgroundPre-clinical modelling of ROS1+ non-small cell lung cancer
Terrones, M., de Beeck, K. O., Camp, G. V., & Vandeweyer, G. (2023) · Lung Cancer · doi:10.1016/j.lungcan.2023.107192 · Cited by 8
Functional impact and molecular binding modes of drugs that target the PI3K isoform p110δ
Hassenrück, F., Farina-Morillas, M., Neumann, L., Landini, F., Blakemore, S. J., Rabipour, M., Alvarez-Idaboy, J. R., Pallasch, C. P., Hallek, M. J., Rebollido-Rios, R., et al. (2023) · Communications Biology · doi:10.1038/s42003-023-04921-z · Cited by 5
Nguyen, T. T. T., Tamai, M., Harama, D., Kagami, K., Kasai, S., Watanabe, A., Akahane, K., Goi, K., & Inukai, T. (2022) · International Journal of Hematology · doi:10.1007/s12185-022-03369-x · Cited by 6
“Pharmaco-biological significance of the BCR/ABL1 mutations in the TKI-sensitivity has been generally tested in murine interleukin-3 (IL-3)-dependent Ba/F3 cells that were introduced BCR/ABL1 or its mutant cDNAs by retrovirus vector [10, 12].”
BackgroundJAK2V617F influences epigenomic changes in myeloproliferative neoplasms
Chen, C., Chiu, C.-C., Lee, K., Hsu, C.-C., Chen, H.-C., Huang, T. H. ‐., Hsiao, S., & Leu, Y. (2017) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2017.10.108 · Cited by 5
Identification of Predictive ERBB Mutations by Leveraging Publicly Available Cell Line Databases
Koivu, M. K. A., Chakroborty, D., Tamirat, M. Z., Johnson, M. S., Kurppa, K. J., & Elenius, K. (2021) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-20-0590 · Cited by 6
“To analyze the activity of the receptor variants in a cellular background devoid of significant endogenous ERBB expression, the IL3dependent Ba/F3 cells (7, 47) were transduced with retroviral vectors encoding the ERBB variants or corresponding wild-type receptors.”
MethodVinyals, A., Ferreres, J. R., Calbet‐Llopart, N., Ramos, R., Tell‐Martí, G., Carrera, C., Marcoval, J., Puig, S., Malvehy, J., Puig‐Butillé, J. A., et al. (2022) · Pigment Cell & Melanoma Research · doi:10.1111/pcmr.13044 · Cited by 5
“Ba/F3 has been widely used to evaluate kinase inhibitors (Warmuth et al., 2007).”
BackgroundMitani, Y., Ohashi, S., Kikuchi, O., Nakai, Y., Ida, T., Mizumoto, A., Yamamoto, Y., Saito, T., Kataoka, S., Matsubara, J., et al. (2022) · Scientific Reports · doi:10.1038/s41598-022-13189-y · Cited by 5
Mand, M. R., Wu, D., Veach, D. R., & Kron, S. J. (2010) · SLAS DISCOVERY · doi:10.1177/1087057110363307 · Cited by 5
“Although this assay was developed to measure Bcr-Abl activity in K562 lysates, it is likely to be useful for other receptor and nonreceptor protein tyrosine kinases,(18) given the availability of specific kinase substrates, and could also be employed for additional nonadherent cells, such as the widely used Ba/F3 cell…”
MethodCellular Ser/Thr-Kinase Assays Using Generic Peptide Substrates
Adams, D. G., Wang, Y., Mak, P. A., Chyba, J., Shalizi, O., Matzen, J., Anderson, P., Smith, T. R., Garcia, M. E., Welch, G. L., et al. (2008) · Current Chemical Genomics · doi:10.2174/1875397300801010054 · Cited by 5
“Ca 2+ -influx assays, cAMP quantitation and other secondary messenger assays for GPCRs or ion channels [3, 4], reporter gene assays for NHRs [5, 6] or Ba/F3 proliferation assays for tyrosine kinases [7, 8] have facilitated the systematic exploitation of traditional drug target families.”
BackgroundClinical and preclinical insights into a novel MDM2::PDGFRA fusion in recurrent glioblastoma
Beach, C. Z., Febres‐Aldana, C. A., Marti, J. L. G., Asiry, S., Wong, T., Boockvar, J. A., D’Amico, R. S., Somwar, R., Davare, M. A., & Vojnic, M. (2025) · npj Precision Oncology · doi:10.1038/s41698-025-01076-4 · Cited by 4
A Cell-Based Assay for Measuring Endogenous BcrAbl Kinase Activity and Inhibitor Resistance
Ouellette, S. B., Noel, B., & Parker, L. L. (2016) · PLoS ONE · doi:10.1371/journal.pone.0161748 · Cited by 4
“Typically, pre-clinical development of TKIs relies on both in vitro and cell-based kinase activity assays to select compounds for further development [10 – 12].”
Maturi, A., Sastry, K. N. V., Kumar, S., Pogaku, V., Kwon, H. J., Ahn, S., & Kim, M. (2024) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.4c00287 · Cited by 4
143D, a novel selective KRASG12C inhibitor exhibits potent antitumor activity in preclinical models
Xu, L., Zheng, S.-X., Mei, L., Yang, K., Wang, Y., Zhou, Q., Kong, X., Zheng, M.-Y., Jiang, H., & Xie, C. (2023) · Acta Pharmacologica Sinica · doi:10.1038/s41401-023-01053-2 · Cited by 5
“Ba/F3 mouse pre-B-cells can grow independently of IL-3 when transformed with an oncogene [31].”
BackgroundCRISPR–Cas9 for Drug Discovery in Oncology
Guichard, S. M. (2017) · Annual reports in medicinal chemistry · doi:10.1016/bs.armc.2017.08.006 · Cited by 4
Kang, C. H., Yun, J. I., Lee, K., Lee, C. O., Lee, H. K., Yun, C., Hwang, J. Y., Cho, S. Y., Jung, H., Kim, P., et al. (2015) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2015.07.027 · Cited by 4
Ex Vivo Transposon-Mediated Genetic Screens for Cancer Gene Discovery
O’Donnell, K. A., Guo, Y., Suresh, S., Updegraff, B. L., & Zhou, X. (2018) · Methods in molecular biology · doi:10.1007/978-1-4939-8967-6_12 · Cited by 3
Therapeutic strategies to overcome ALK resistance in lung cancer
Recondo, G., & Friboulet, L. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-821774-0.00004-8 · Cited by 2
Ouyang, X., Grandinetti, K. B., Boren, M., Chakravorty, S. J., Chopade, S., Jiang, P., Kanouni, T., Koudriakova, T. B., Makwana, O., Pack, S. K., et al. (2025) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5c00834 · Cited by 2
Xq24/ IL13RA1 aberrations as key drivers of female bias in primary mediastinal large B‐cell lymphoma
Marcelis, L., Allsop, R., Bempt, M. V., Debackere, K., Renard, F., Tuveri, S., Dierickx, D., Janiszewski, A., Balaton, B. P., Vets, J., et al. (2025) · HemaSphere · doi:10.1002/hem3.70200 · Cited by 2
C-Terminal Truncation and Fusion Partner Determine Oncogenicity of FGFR3
Yemelyanenko, J., Bhin, J., van der Burg, E., Drenth, A. P., Lee, J., Lutz, C., Dörner, L., Wientjens, E., Klarenbeek, S., Song, J., et al. (2025) · Cancer Research · doi:10.1158/0008-5472.can-24-2648 · Cited by 2
Zheng, J., Zhao, S., Zhan, J., Zhuang, W., Chen, M., Jiang, W., Huang, Y., He, J., Hu, L., Pang, L., et al. (2026) · Cancer Discovery · doi:10.1158/2159-8290.cd-25-1936 · Cited by 2
Fernandes, J. C., Fenerich, B. A., Alves-Silva, A. B., Fonseca, N. P., Coelho‐Silva, J. L., Scheucher, P. S., Rego, E. M., de Figueiredo‐Pontes, L. L., Machado‐Neto, J. A., & Traina, F. (2022) · Toxicology in Vitro · doi:10.1016/j.tiv.2022.105384 · Cited by 2
Mendivil‐Perez, M., Jiménez-Del-Río, M., & Velez‐Pardo, C. (2022) · Medical Oncology · doi:10.1007/s12032-022-01873-y · Cited by 2
“Since Ba/F3 is an IL-3-dependent pro-B-cell line amenable to be transformed into an IL-3-independent pro-Bcell line by expression of oncogenic kinase BCR-ABL protein [19, 20], we used plasmid BCR/ABL P210-pLEF to transform naïve Ba/F3 cells.”
Progression and perspectives in disease modeling for Juvenile myelomonocytic leukemia
Fu, S., Guo, Y., Peng, Z., Zhang, D., Chang, Z., Xiao, Y., Zhang, Q., Yu, L., Chen, C., Chen, Y., et al. (2024) · Medical Oncology · doi:10.1007/s12032-024-02549-5 · Cited by 2
[Molecular therapeutics in patients with cancer unresponsive to conventional treatments].
Valdespino-Gómeza, V. M., & Valdespino-Castillo, V. E. (2008) · PubMed · Cited by 2
Libre, C., Moro-Sibilot, L., Giraud, S., Martin, L., Verhoeyen, E., Costa, C., Chebel, A., Bissay, N., Salles, G. A., Genestier, L., et al. (2020) · Cancers · doi:10.3390/cancers12040901 · Cited by 2
“Lentiviral vectors were produced as previously described [10].”
BackgroundMethodInfluentialLacy, D. C., Heppner, D. E., Buckley, B., Griffiths, J., Gunasekera, P. S., Patel, J., Roche-Rivera, Z., Coppola, K., Dempsey, K., Pillai, S. C., et al. (2024) · Polyhedron · doi:10.1016/j.poly.2024.116859 · Cited by 2
Estevam, G. O., Linossi, E. M., Macdonald, C. B., Espinoza, C. A., Michaud, J. M., Coyote‐Maestas, W., Collisson, E. A., Jura, N., & Fraser, J. S. (2023) · eLife · doi:10.7554/elife.91619.1 · Cited by 5
Estevam, G. O., Linossi, E. M., Macdonald, C. B., Espinoza, C. A., Michaud, J. M., Coyote‐Maestas, W., Collisson, E. A., Jura, N., & Fraser, J. S. (2024) · eLife · doi:10.7554/elife.91619.2 · Cited by 2
Hinge binder modification into imidazopyridine for targeting actionable mutations of RET kinase
Maturi, A., Pogaku, V., Kumar, S., & Kim, M. (2025) · RSC Medicinal Chemistry · doi:10.1039/d5md00397k · Cited by 1
Hudkins, R. L., Allen, E., Iyer, S., Balcer, A., Neal, M., Ye, Q., Rideout, M., Frye, C. B., Nelson, K. J., Hoffman, I., et al. (2026) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6c00514 · Cited by 1
Understanding and Using Information about Cancer Genomes
Spellman, P. T., Stuart, J. M., & Gray, J. W. (2015) · Elsevier eBooks · doi:10.1016/b978-1-4557-4066-6.00024-x
Drug Resistance Against Tyrosine Kinase Inhibitor in Gastrointestinal Malignancies
Bhaskar, L. V., & Saikrishna, L. (2018) · Springer eBooks · doi:10.1007/978-981-13-1486-5_14
Metadata
- Authors
- Warmuth, M., Kim, S., Gu, X.-J., Xia, G., & Adrián, F.
- Affiliations
- Genomics Institute of the Novartis Research Foundation (US)
- Corresponding author
- Warmuth, Markus
- ORCID
- Xia, Gang
- Venue
- Current Opinion in Oncology
- Published
- 2007-01
- Volume
- 19
- Issue
- 1
- Pages
- 55-60
- ISSN
- 1040-8746 (ISSN-L)
- OpenAlex
- W2088757697
- Cited by
- 240
- References
- 60
- Citations by year
- 2026: 7 · 2025: 14 · 2024: 27 · 2023: 22 · 2022: 25 · 2021: 19 · 2020: 18 · 2019: 5 · 2018: 13 · 2017: 14 · 2016: 14 · 2015: 9 · 2014: 11 · 2013: 10 · 2012: 7
- FWCI
- 0.63
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Current Opinion in Oncology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Mechanisms and Therapy
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Kinase Regulation and GTPase Signaling
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
- Keywords
- Ba/F3 cells, protein kinases, kinase inhibitors, kinase drug discovery, oncogenes, small-molecule kinase inhibitors, high-throughput screening, compound profiling, drug resistance prediction, point mutations, downstream signaling, interleukin-3 dependence
- MeSH terms
- Animals, Antineoplastic Agents, Cell Line, Cell Transformation, Neoplastic, Epidermal Growth Factor, Drug Design, Signal Transduction, Drug Resistance, Neoplasm, Protein Kinase Inhibitors, Mice, ErbB Receptors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.